Medigen Biotechnology (3176) Fundamentals 2026 — Revenue Analysis | SniperIQ
Medigen Biotechnology (3176) is a TW-listed Healthcare company in Biotechnology with a market capitalization of NT$4.8B, trading at NT
Medigen Biotechnology (3176) is a TW-listed Healthcare company in Biotechnology with a market capitalization of NT$4.8B, trading at NT
Medigen Biotechnology (3176) has a market capitalization of approximately NT$4.8B, trading at NT
Medigen Biotechnology's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Medigen Biotechnology runs a net profit margin of -19.0%, a gross margin of 48.1%, and an operating margin of -23.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Medigen Biotechnology reported revenue of NT
Medigen Biotechnology does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Medigen Biotechnology carries a debt-to-equity ratio of 1.17x and a current ratio of 5.41x, with a market beta of 0.25. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Medigen Biotechnology (3176) the key facts are: market cap NT$4.8B, revenue NT
Get Medigen Biotechnology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.